F034 Finding Solutions to Challenging Cases
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session highlights rising junior academic faculty, each of whom will present a handful of challenging patient cases encountered in their practice. Focus will be on diagnostic dilemmas, management pearls, and therapeutic triumphs. The discussion is meant to be interactive utilizing the audience response system. This activity has been approved by the American Board of Dermatology (ABD) for up to 20 Continuous Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Formulate diagnostic algorithms for challenging cases.
Identify novel therapeutic considerations for difficult clinical scenarios.
SCHEDULE
11:30 PM
Finding Solutions to Challenging Cases: Faculty Introductions
Sonal D. Shah, MD, FAAD
11:40 PM
Finding Solutions to Challenging Cases
Timmie Rohi Sharma, MD, FAAD
12:05 AM
Finding Solutions to Challenging Cases
Sean Denis Reynolds, MD, FAAD
12:30 AM
Finding Solutions to Challenging Cases
Sarah Jane Coates, MD, FAAD
12:55 AM
Finding Solutions to Challenging Cases
Prince Adotama, MD, FAAD
SPEAKERS
Prince Adotama, MD, FAAD
Sarah Jane Coates, MD, FAAD
Sean Denis Reynolds, MD, FAAD
Sonal D. Shah, MD, FAAD
Timmie Rohi Sharma, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Prince Adotama, MD, FAAD
arGEN-X – Advisory Board(Honoraria); Bristol-Myers Squibb – Consultant (1099 relationship)(Honoraria); Catalyst Medical Education LLC – Speaker(Honoraria); Janssen Scientific Affairs, LLC – Advisory Board(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria);
Sarah Jane Coates, MD, FAAD
No financial relationships exist with ineligible companies.
Sean Denis Reynolds, MD, FAAD
No financial relationships exist with ineligible companies.
Sonal D. Shah, MD, FAAD
UpToDate, Inc – Independent Contractor(Patent royalties or other compensation for Intellectual Property Rights);
Timmie Rohi Sharma, MD, FAAD
No financial relationships exist with ineligible companies.